[The future of depression: a complex neuroendocrine, inflammatory and neurodegenerative systemic illness].
Neurobiological models of depression have evolved far beyond the monoamine theory that was construed following the advent of antidepressant drugs in the 1950s. Depression is now seen to implicate a wide range of neurotransmitters, including dopamine and glutamate, and virtually the entire central nervous system. Emerging evidence is redefining depression as a chronic and systemic illness that may impair neuroendocrine function, biological rhythms and immune responses, and one which may lead to dementia if left untreated. Different research approaches, from molecular biology to clinical studies, have offered new insights into the physiological mechanisms involved as well as indications of how effective antidepressant therapies may develop in response to these. In addition to well-established methods, like monoamine reuptake inhibitors and cognitive behavioural therapy, these may include non-steroid anti-inflammatory drugs, prescription of physical exercise, somatic treatments and a whole new generation of antidepressant drugs endowed with original modes of action. As the management of depression becomes increasingly multifaceted, clinicians will be able to optimise clinical outcomes for their patients by synergistically integrating the multiple therapeutic options available.
Dratcu
Luiz
L
York Clinic, Guy's Hospital, South London, UK.
D003863:Depression / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D004700:Endocrine System Diseases / Q000150:complications; D005544:Forecasting; D006801:Humans; D007249:Inflammation / Q000150:complications; D019636:Neurodegenerative Diseases / Q000150:complications